FDA Approves Treatment For Meibomian Gland Dysfunction

Monday, July 11, 2011

Comments

Ocular Surgery News

TearScience has received approval from the U.S. Food and Drug Administration to market a thermal pulsation system used to treat meibomian gland dysfunction, the company announced in a press release.

Full Story

The lesion seen below has been present for many years. The patient does not complain of pain, itching or growth. This is most consistent with:
1. apocrine hydrocystoma
2. basal cell carcinoma
3. chronic dacryocystitis
4. sebaceous cell carcinoma
Check The Answer

CareCloud Charts For Ophthalmology
Get all of the tools you need to deliver... view product
Smartphone-Based Retinal Screening System
D-EYE, The Modern Day Digital ... view product

View all Featured Products »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Like us
on Facebook Follow us
on Twitter

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

Learn more about writing for us

AdGlare Leaderboard

FDA Approves Treatment For Meibomian Gland Dysfunction

Comments

Quick Quiz

The lesion seen below has been present for many years. The patient does not complain of pain, itching or growth. This is most consistent with:

AdGlare RMR Ad

Featured Products

CareCloud Charts For Ophthalmology

Smartphone-Based Retinal Screening System

Follow OphthalmologyWeb

AdGlare RMR2

Write for Us